Keywords: basement membrane; epithelial cell; extracellular matrix; glomerulosclerosis; microalbuminuria; Background. Detection of podocytes in the urinary sediments of children with glomerulonephritis has been podocalyxin shown to indicate severe injury to the podocytes. The aim of the present study was to determine whether podocytes are present in the urine sediments of adult Introduction patients with diabetes with and without nephropathy and whether trandolapril is effective for podocyte Podocytes are thought to support the glomerular baseinjury. ment membrane, and the integrity of these cells and Methods. Fifty diabetic patients (10 with normoalbu-structural preservation of their foot processes are minuria, 15 with microalbuminuria, 15 with macroal-important in glomerular filtration [1] . Podocytes are buminuria and 10 with chronic renal failure) and 10 target cells in the glomerulus for various stimuli, and healthy controls were studied. Urinary podocytes were podocyte injury occurs to varying degrees in patholoexamined by immunofluorescence using monoclonal gical conditions. Podocytes are located on the outer antibodies against podocalyxin, which is present on surface of the glomerular basement membrane; thus, the surface of podocytes. In addition, we studied injured podocytes or related structures appear in the plasma metalloproteinase (MMP)-9 concentrations in urine if injury to the cell is serious enough. A glomerall patients. ular epithelial cell antigen, podocalyxin, has been found Results. Urinary podocytes were absent in healthy in the urine of patients with glomerular disease [2, 3] . controls, diabetic patients with normoalbuminuria and Hara et al. detected podocalyxin-marked podocytes in diabetic patients with chronic renal failure. Podocytes urinary sediments of patients with various forms of were detected in the urine of eight diabetic patients glomerulonephritis and reported that the number of with microalbuminuria (53%) and of 12 patients with podocytes in the urine was a direct indication of the macroalbuminuria (80%). The number of podocytes degree of glomerular epithelial cell injury in children in the urine of patients with macroalbuminuria was with glomerular disease [4, 5] . Urinary podocytes significantly greater than in patients with microalbumi-recently were described as a marker for estimating the nuria (P<0.01). However, there was no relationship severity of active glomerular injury and a predictor of between urinary albumin excretion and urinary podo-disease progression [6 ] . However, little is known about cytes. In addition, plasma MMP-9 concentrations were urinary podocyte excretion in diabetic nephropathy significantly correlated with the number of urinary in adults. podocytes (P<0.01). Twelve diabetic patients with Metalloproteinase (MMP)-9 has a broad substrate macroalbuminuria and eight patients with microalbu-specificity for native collagens, proteoglycans and elasminuria who had urinary podocytes were treated with tin [7] . MMP-9 has been identified in a variety of the angiotensin-converting enzyme inhibitor trandolap-tissues and body fluids under pathophysiological condiril. Urinary albumin excretion, the number of podo-tions including smoking, cancers and polycystic kidney cytes and plasma MMP-9 concentrations were reduced diseases [8] [9] [10] . We recently have reported that an by the trandolapril treatment.
>1.5 mg/dl, creatinine clearance<80 ml/min) were included diabetic patients with nephropathy [11, 13, 14] .
Trandolapril is a new, orally active, long-lasting nonImmunofluorescent staining of urinary podocytes was persulfhydryl ACE inhibitor ideal for a once-daily regimen formed as previously described [4, 6 ] . Urine sediments were [15] . The aim of the present study was to determine cytospun on glass slides and incubated with anti-human whether urinary podocytes are detected in patients podocalyxin monoclonal antibody PHM5 (Australian with diabetes and whether trandolapril affects the Monoclonal Development, Australia). This antibody reacts number of podocytes in the urine.
with a 165-170 kDa band of podocalyxin, as demonstrated by immunoblot analysis, on podocytes in human kidney immunohistology sections [6 ] . This antibody stained glomer-
Materials and methods
ular epithelial cells intensely and endothelial cells faintly in normal kidney sections. The staining was virtually identical Ten diabetic patients with normoalbuminuria (group A), 15 in all these glomeruli regardless of the type of glomerular diabetic patients with microalbuminuria (group B), 15 dia-diseases. However, the glomerular epithelial cells adjacent to betic patients with macroalbuminuria (group C ) and 10 adhesions or crescents were not stained with this antibody patients with chronic renal failure (group D) with non- [4] . Western blot analysis of this antibody was performed by insulin-dependent diabetes mellitus (NIDDM ) and 10 Hara et al. [4] . They also reported the fine structure of the healthy controls were recruited for the present study and podocalyxin-positive cells in the urinary sediments by gave informed consent. NIDDM was diagnosed according immunoelectron microscopy using this antibody [4] . The to World Health Organization criteria. Insulin was not surface of these cells has many short villous structures visible necessary for at least 3 years from the onset of diabetes, and with labelled anti-podocalyxin antibody. The diameter of the body weight was stable in the last years (2.8±0.1%). There villous structures is similar to that of fine granules identified was no malignancy or history of heart disease, cerebrovascu-by immunofluorescence microscopy. After washing, slides lar disease, liver disease or collagen disease in patients in were incubated with fluorescein isothiocyanate-labelled groups A-C, and they had normal blood pressure. Clinical F(ab∞) 2 fragments of affinity-purified anti-mouse IgG and laboratory data of subjects is shown in Table 1 . After (Cappel, USA). Slides were washed and examined under an an overnight fast, blood was drawn from an antecubital vein immunofluorescence microscope. The nuclei of cells were for measurement of glucose, glycated haemoglobin and serum counterstained with ethidium bromide. We reported previcreatinine concentration. Plasma glucose concentration was ously that podocalyxin was present in the urinary sediments determined by the glucose oxidase method, and plasma-of patients with glomerular diseases in the following three glycated haemoglobin concentration was measured by spec-patterns: cast, fine granules and entire cells [4] . In the present trophotometric assay (Bio-Rad, Richmond, VA; normal study, we measured entire cells, not cell fragments, in the range, 3.5-6.5%). Normal blood pressure values (systolic urine. blood pressure <140 mmHg, diastolic blood pressure
To measure the plasma concentrations of MMP-9, a one-<90 mmHg) were observed on two consecutive examinations step sandwich enzyme immunoassay using two monoclonal [14] . On the basis of median urinary albumin excretion antibodies was used as previously described [16 ] . The sensit-( UAE) from at least three consecutive 4-h urine collections ivity of the assay system was 0.24 ng/ml (2.2 pg/assay), (taken in the morning), patients were classified as follows; and linearity was obtained from 0.24 to 250 ng/ml microalbuminuria was defined as a median UAE of (2.2-2280 pg/assay). The intra-assay coefficient of variation 20-200 mg/min and macroalbuminuria as UAE>200 mg/min. ranged from 1.8 to 3.9%, while the inter-assay coefficient ranged from 1.8 to 6.2% [8, 9, 11, 16 ] . Patients with renal dysfunction (serum creatinine Patients with microalbuminuria or macroalbuminuria who largest number of urinary podocytes, but the least demonstrated urinary podocytes were treated with oral tran-urinary albumin excretion. In group C, urinary albudolapril (Chugai Co., Ltd, Tokyo, Japan; 1 mg/day) for 2 min in patients who had positive urinary podocytes months, and urinary podocytes and plasma MMP-9 concen-(mean: 936.7 mg/min) was less than that in patients trations were examined after treatment.
who had negative urinary podocytes (mean: Data are expressed as mean ±standard deviation. 1073.3 mg/min). There was also no relationship Statistical analyses were performed using analysis of variance between blood glucose level or blood pressure and the and the Mann-Whitney U-test.
number of podocalyxin-positive cells (P=0.09 and 0.08, respectively; not significant). In addition, there was no relationship between glycaemic control, diabetic Results duration and the number of urinary podocytes (P= 0.08 and 0.10, respectively; not significant). None of Podocalyxin-positive cells are shown in Figure 1 . the diabetic patients with normoalbuminuria or with Podocalyxin-positive cells were detected in the urinary chronic renal failure and none of the healthy controls sediments of eight out of 15 patients with microalbumi-had urinary podocytes. nuria (53%) (range: 0.8-1.9 cells/ml ) and 12 out of 15
Plasma MMP-9 concentrations in 20 diabetic patients with macroalbuminuria (80%) (range: 0.8-5.3 patients with detectable urinary podocyte excretion cells/ml ). Urinary albumin excretion and urinary podo-(microalbuminuric patients, n=8 and macroalbumincytes are shown in Figure 2 . There was no relationship uric patients, n=12: 86.4±36.6 ng/ml ) were significbetween the degree of albuminuria and the number of antly higher than those in 10 diabetic patients with podocalyxin-positive cells. In group B, urinary albumin undetectable urinary podocyte excretion (microalbumiexcretion in patients who had positive urinary nuric patients, n=7 and macroalbuminuric patients, podocytes (mean: 53.8 mg/min) was less than that in n=3: 52.6±22.8 ng/ml, P<0.05) and healthy controls patients who had negative urinary podocytes (mean: (30.6±10.8 ng/ml, P<0.01) (Figure 3 ). 126.3 mg/min). Patient number 1 in group B had the Urinary albumin excretion and urinary podocytes before and 2 months after trandolapril treatment in eight diabetic patients with microalbuminuria and 12 patients with macroalbuminuria are shown in Figure 4 . Trandolapril reduced urinary albumin excretion in all patients (group B, from 53.8±26.2 mg/min to 17.3±8.2 mg/min, P<0.01; group C, from 936.7± 282.6 mg/min to 151.3±36.2 mg/min, P<0.001). Trandolapril also reduced the number of podocytes in the urine (group B; mean, from 1.25 cells/ml to 0.08 cells/ml, P<0.01, group C; mean, from 2.03 cells/ml to 0.13 cells/ml, P<0.01). Trandolapril reduced plasma MMP-9 concentrations in 20 diabetic patients with detectable urinary podocyte excretion (from 86.4±36.6 ng/ml to 54.8±22.6 ng/ml, P<0.05). Trandolapril did not affect serum creatinine and glycated haemoglobin levels in groups B and C. Fig. 2 . Urinary albumin excretion (mg/min) (A) and urinary podocytes (cells/ml ) (B) in diabetic patients. Group B: microalbuminuric in diabetic patients with detectable urinary podocytes, in diabetic patients with undetectable urinary podocytes and in healthy controls. patients; group C: macroalbuminuric patients. *P <0.01; **P <0.001. *P <0.05; **P <0.01. glomerular capillary pressure, microalbuminuria could reflect intrinsic glomerular damage causing changes in glomerular barrier function [19] . Recently, Meyer et al. [20] reported that among glomerular morphological characteristics, the number of podocytes per glomerulus was the strongest predictor of renal disease progression in diabetics. Since podocytes are thought to be incapable of replication, podocyte loss or a low podocyte number per glomerulus contributes to the development and progression of glomerulosclerosis [17] . Therefore, the detection of podocytes in the urine sediments is a simple and non-invasive procedure to examine podocyte injury. In diabetic patients, there is a close association between microalbuminuria and epithelial dysfunction Fig. 4 . Urinary albumin excretion (mg/min) (A) and urinary podo- [21] . We previously have reported that an increase in cytes (cells/ml ) (B) in diabetic patients before and after 2 month of plasma MMP-9 preceded the occurrence of microalbutrandolapril treatment. Group B: microalbuminuric patients; group minuria in diabetic patients [11] . McMillan et al. [22] C: macroalbuminuric patients. *P <0.01; **P <0.001.
reported increased glomerular epithelial cell MMP-9 expression to be correlated with the period of proTrandolapril reduced blood pressure from 120± teinuria in rat Heymann nephritis and that a direct 14 mmHg to 108±8 mmHg in group B (P<0.05) and link exists between glomerular epithelial cell proteolytic from 122±16 mmHg to 110±10 mmHg in group C activities and loss of glomerular permselectivity. We (P<0.05).
speculated that one of the sources of increased plasma MMP-9 levels may be epithelial cells, and observed that diabetic patients with urinary podocytes showed
Discussion
high plasma MMP-9 concentrations ( Figure 3 ). ACE inhibitors decrease proteinuria and slow the progression of diabetic nephropathy by mechanisms In contrast to urine samples from diabetic patients with normoalbuminuria, diabetic patients with chronic that cannot be attributed solely to effective control of systemic hypertension. Some investigators have renal failure and healthy controls, podocytes were detected in urinary sediments obtained from diabetic reported the efficacy of ACE inhibitors in reducing the risk of developing end-stage renal disease in NIDDM patients with microalbuminuria and diabetic patients with macroalbuminuria. Daniels reported that in con-patients [13, 23] . Trandolapril is effective in diabetic nephropathy in rats and humans [24, 25] . In the present junction with the glomerular basement membrane, the glomerular podocyte plays an important role in glomer-study, trandolapril reduced urinary albumin excretion and plasma MMP-9 concentrations, as well as urinary ular filtration [1] . The loss of podocytes from the glomerular basement membrane impairs the glomer-podocytes in patients with diabetic nephropathy.
However, the precise mechanism by which ACE inhibular filtration process.
Analyses of kidney biopsies from Pima Indians with itors act on urinary podocytes is still unknown. We are now studying the effect of other anti-hypertensive NIDDM demonstrated that subjects with clinical nephropathy exhibited broadening of podocyte foot drugs including calcium channel antagonists and angiotensin II receptor antagonists on urinary podocyte processes associated with a reduction in the number of podocytes per glomerulus and an increase in the excretion in diabetic patients.
Unexpectedly, diabetic patients with chronic renal surface area covered by remaining podocytes, suggesting that podocyte loss contributes to the progres-failure had no podocyte excretion in the urine. We recognized that urinary podocytes were absent in sion of diabetic nephropathy [17] . Focal detachment of podocytes from the glomerular basement membrane chronic renal failure patients with a variety of glomerular diseases such as IgA nephropathy, focal may be associated with a decrease in a3b1 integrin at the podocyte basal plasma membrane, which occurs glomerulosclerosis, membranous nephropathy and membranoproliferative glomerulonephritis (unpubas early as 1 month after of hyperglycaemia [18] . It is possible to count the number of lost podocytes in the lished data). These results suggest that the presence of urinary podocytes may be a marker of disease severity urine since podocytes are located in the urinary space of the glomerular capillary walls and, therefore, appear during the active phase of glomerular injury, but not during the chronic progressive phase of glomerular in the urine if they are lost from the glomerular basement membrane. Hara et al. reported that a con-disease.
In summary, detection of podocytes in the urinary siderable number of podocytes exists in the urine of children with various glomerular diseases [4, 6 ] . sediments by immunofluorescence indicates that glomerular epithelial cell injury occurs in patients with However, little is known about adults with diabetic nephropathy. Since increased urinary albumin excre-diabetic nephropathy. Trandolapril may have a beneficial effect on glomerular epithelial cell injury. tion could be the consequence of augmented intra-
